Heights Capital Management’s BriaCell Therapeutics Corp Warrant BCTXZ Stock Holding History

Heights Capital Management’s Portfolio BCTXZ Stock Details BCTXZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$75.6K	Sell	540,098 -4,600	-0.8%	-$772	0.02%	172
2025 Q4	$163K	Hold	544,698	–	–	0.06%	121
2025 Q3	$186K	Sell	544,698 -7,383	-1%	-$2.45K	0.05%	111
2025 Q2	$574K	Buy	+552,081	New	+$596K	0.15%	69

Other funds holding BCTXZ

EAM

Empery Asset Management New York $83M AUM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Heights Capital Management's BCTXZ Position: Q1 2026 in Review

Heights Capital Management reduced its BriaCell Therapeutics Corp Warrant (BCTXZ) stake by 0.84% in Q1 2026, selling an estimated $772 and leaving 540,098 shares worth $75.6K. The position accounts for 0.02% of the portfolio, ranked #172.

Heights Capital Management first reported a position in BCTXZ in Q2 2025 and has held it in 4 quarters since. The position peaked at $574K in Q2 2025. 4 funds tracked by Wall St. Rank hold BCTXZ as of Q1 2026.

Heights Capital Management held 540,098 shares of BriaCell Therapeutics Corp Warrant worth $75.6K as of Q1 2026.
Heights Capital Management sold 4,600 BriaCell Therapeutics Corp Warrant shares in Q1 2026, an estimated $772.
BriaCell Therapeutics Corp Warrant made up 0.02% of Heights Capital Management's portfolio in Q1 2026, its #172 holding.
Heights Capital Management first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2025 and has held it in 4 quarters since.
Heights Capital Management's BriaCell Therapeutics Corp Warrant position peaked at $574K in Q2 2025.
4 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q1 2026.

Based on Heights Capital Management's 13F filing for Q1 2026, filed 15 May 2026.